Published in AIDS Weekly, September 11th, 2006
In addition, the design and physical characteristics of FC2, supported by the clinical data, suggest that the two devices are functionally equivalent, when used correctly. Based on this assessment WHO has stated that FC2 product is acceptable for bulk procurement by...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.